Mesenchymal stem cells in cardiology

Methods in Molecular Biology

Volumn 1416, Issue , 2016, Pages 55-87

  White, Ian A ^a   Sanina, Cristina ^a   Balkan, Wayne ^a   Hare, Joshua M ^a  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

Cardiology; Cardiovascular Disease; Clinical trial; Mesenchymal stem cell; Myocardial infarction

Indexed keywords

ANGIOGENESIS; CARDIAC MUSCLE CELL; CARDIAC STEM CELL; CARDIOLOGY; CARDIOVASCULAR DISEASE; CELL DIFFERENTIATION; CELL PROLIFERATION; ENDOTHELIUM CELL; HEART DISEASE; HEART INJURY; HEART MUSCLE FIBROSIS; HUMAN; IMMUNOBIOLOGY; IMMUNOREACTIVITY; ISCHEMIC PRECONDITIONING; MESENCHYMAL STEM CELL; MESENCHYMAL STEM CELL TRANSPLANTATION; NONHUMAN; PARACRINE SIGNALING; VASCULAR SMOOTH MUSCLE CELL; ANIMAL; CELL CULTURE; CLINICAL TRIAL (TOPIC); CYTOLOGY; HEART SURGERY; MESENCHYMAL STROMA CELL; PROCEDURES; SECRETION (PROCESS); TREATMENT OUTCOME;

ANIMALS; CARDIAC SURGICAL PROCEDURES; CARDIOVASCULAR DISEASES; CELL DIFFERENTIATION; CELL PROLIFERATION; CELLS, CULTURED; CLINICAL TRIALS AS TOPIC; HUMANS; MESENCHYMAL STEM CELL TRANSPLANTATION; MESENCHYMAL STROMAL CELLS; TREATMENT OUTCOME;

EID: 84990230741     PISSN: 10643745     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-1-4939-3584-0_4     Document Type: Chapter

References (173)

1. Vodyanik MA, Yu J, Zhang X et al (2010) A mesoderm-derived precursor for mesenchymal stem and endothelial cells. Cell Stem Cell 7:718-729
2. Abu-Issa R, Kirby ML (2007) Heart field: from mesoderm to heart tube. Annu Rev Cell Dev Biol 23:45-68
3. Brand T (2003) Heart development: molecular insights into cardiac specification and early morphogenesis. Dev Biol 258:1-19
4. Montserrat N, Jopling C, Izpisua Belmonte JC (2010) Understanding the molecular basis for cardiomyocyte cell cycle regulation: new insights in cardiac regeneration after injury? Expert Rev Cardiovasc Ther 8:1043-1045
5. Pasumarthi KB, Field LJ (2002) Cardiomyocyte cell cycle regulation. Circ Res 90:1044-1054
6. MacLellan WR, Schneider MD (2000) Genetic dissection of cardiac growth control pathways. Annu Rev Physiol 62:289-319
7. Kang PM, Izumo S (2000) Apoptosis and heart failure: a critical review of the literature. Circ Res 86:1107-1113
8. Porrello ER, Mahmoud AI, Simpson E et al (2011) Transient regenerative potential of the neonatal mouse heart. Science 331:1078-1080
9. Bergmann O, Bhardwaj RD, Bernard S et al (2009) Evidence for cardiomyocyte renewal in humans. Science 324:98-102
10. Go AS, Mozaffarian D, Roger VL et al (2014) Heart disease and stroke statistics—2014 update: a report from the American Heart Association. Circulation 129:e28-e292
11. Jennings RB, Steenbergen C, Reimer KA (1995) Myocardial ischemia and reperfusion. Monogr Pathol 37:47-80
12. Graham RM, Frazier DP, Thompson JW et al (2004) A unique pathway of cardiac myocyte death caused by hypoxia-acidosis. J Exp Biol 207:3189-3200
13. Kubasiak LA, Hernandez OM, Bishopric NH et al (2002) Hypoxia and acidosis activate cardiac myocyte death through the Bcl-2 family protein BNIP3. Proc Natl Acad Sci U S A 99:12825-12830
14. Laflamme MA, Murry CE (2005) Regenerating the heart. Nat Biotechnol 23:845-856
15. Becker RO, Chapin S, Sherry R (1974) Regeneration of the ventricular myocardium in amphibians. Nature 248:145-147
16. Poss KD, Wilson LG, Keating MT (2002) Heart regeneration in zebrafish. Science 298:2188-2190
17. Hatzistergos KE, Blum A, Ince T et al (2011) What is the oncologic risk of stem cell treatment for heart disease? Circ Res 108:1300-1303
18. Menasche P, Hagege AA, Vilquin JT et al (2003) Autologous skeletal myoblast transplantation for severe postinfarction left ventricular dysfunction. J Am Coll Cardiol 41:1078-1083
19. Menasche P (2003) Myoblast-based cell transplantation. Heart Fail Rev 8:221-227
20. Beltrami AP, Barlucchi L, Torella D et al (2003) Adult cardiac stem cells are multipotent and support myocardial regeneration. Cell 114:763-776
21. Bolli R, Chugh AR, D'Amario D et al (2011) Cardiac stem cells in patients with ischaemic cardiomyopathy (SCIPIO):initial results of a randomised phase 1 trial. Lancet 378: 1847-1857
22. Caplan AI (1991) Mesenchymal stem cells. J Orthop Res 9:641-650
23. Caplan AI (1986) Molecular and cellular differentiation of muscle, cartilage, and bone in the developing limb. Prog Clin Biol Res 217B:307-318
24. Friedenstein AJ, Chailakhjan RK, Lalykina KS (1970) The development of fibroblast colonies in monolayer cultures of guinea-pig bone marrow and spleen cells. Cell Tissue Kinet 3:393-403
25. Friedenstein AJ, Chailakhyan RK, Latsinik NV et al (1974) Stromal cells responsible for transferring the microenvironment of the hemopoietic tissues. Cloning in vitro and retransplantation in vivo. Transplantation 17:331-340
26. Dominici M, Le Blanc K, Mueller I et al (2006) Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy 8:315-317
27. da Silva Meirelles L, Chagastelles PC, Nardi NB (2006) Mesenchymal stem cells reside in virtually all post-natal organs and tissues. J Cell Sci 119:2204-2213
28. Orbay H, Tobita M, Mizuno H (2012) Mesenchymal stem cells isolated from adipose and other tissues: basic biological properties and clinical applications. Stem Cells Int 2012:461718
29. Crisan M, Yap S, Casteilla L et al (2008) A perivascular origin for mesenchymal stem cells in multiple human organs. Cell Stem Cell 3:301-313
30. Mendez-Ferrer S, Michurina TV, Ferraro F et al (2010) Mesenchymal and haematopoietic stem cells form a unique bone marrow niche. Nature 466:829-834
31. Winkler EA, Bell RD, Zlokovic BV (2011) Central nervous system pericytes in health and disease. Nat Neurosci 14:1398-1405
32. Roufosse CA, Direkze NC, Otto WR et al (2004) Circulating mesenchymal stem cells. Int J Biochem Cell Biol 36:585-597
33. He Q, Wan C, Li G (2007) Concise review: multipotent mesenchymal stromal cells in blood. Stem Cells 25:69-77
34. Caterson EJ, Nesti LJ, Danielson KG et al (2002) Human marrow-derived mesenchymal progenitor cells: isolation, culture expansion, and analysis of differentiation. Mol Biotechnol 20:245-256
35. Chang Y, Hsieh PH, Chao CC (2009) The efficiency of Percoll and Ficoll density gradient media in the isolation of marrow derived human mesenchymal stem cells with osteogenic potential. Chang Gung Med J 32:264-275
36. Harichandan A, Sivasubramaniyan K, Buhring HJ (2013) Prospective isolation and characterization of human bone marrow-derived MSCs. Adv Biochem Eng Biotechnol 129:1-17
37. Lennon DP, Caplan AI (2006) Isolation of human marrow-derived mesenchymal stem cells. Exp Hematol 34:1604-1605
38. Majumdar MK, Banks V, Peluso DP et al (2000) Isolation, characterization, and chondrogenic potential of human bone marrowderived multipotential stromal cells. J Cell Physiol 185:98-106
39. Wolfe M, Pochampally R, Swaney W et al (2008) Isolation and culture of bone marrowderived human multipotent stromal cells (hMSCs). Methods Mol Biol 449:3-25
40. Colter DC, Class R, DiGirolamo CM et al (2000) Rapid expansion of recycling stem cells in cultures of plastic-adherent cells from human bone marrow. Proc Natl Acad Sci U S A 97:3213-3218
41. Zhou Z, Jiang EL, Wang M et al (2005) Comparative study on various subpopulations in mesenchymal stem cells of adult bone marrow. Zhongguo Shi Yan Xue Ye Xue Za Zhi 13:54-58
42. Jiang Y, Jahagirdar BN, Reinhardt RL et al (2002) Pluripotency of mesenchymal stem cells derived from adult marrow. Nature 418:41-49
43. Jiang Y, Vaessen B, Lenvik T et al (2002) Multipotent progenitor cells can be isolated from postnatal murine bone marrow, muscle, and brain. Exp Hematol 30:896-904
44. Yoon YS, Wecker A, Heyd L et al (2005) Clonally expanded novel multipotent stem cells from human bone marrow regenerate myocardium after myocardial infarction. J Clin Invest 115:326-338
45. D'Ippolito G, Diabira S, Howard GA et al (2004) Marrow-isolated adult multilineage inducible (MIAMI) cells, a unique population of postnatal young and old human cells with extensive expansion and differentiation potential. J Cell Sci 117:2971-2981
46. Rossini A, Frati C, Lagrasta C et al (2011) Human cardiac and bone marrow stromal cells exhibit distinctive properties related to their origin. Cardiovasc Res 89:650-660
47. Blazquez-Martinez A, Chiesa M, Arnalich F et al (2014) c-Kit identifies a subpopulation of mesenchymal stem cells in adipose tissue with higher telomerase expression and differentiation potential. Differentiation 87(3-4):147-160
48. Varma MJ, Breuls RG, Schouten TE et al (2007) Phenotypical and functional characterization of freshly isolated adipose tissuederived stem cells. Stem Cells Dev 16: 91-104
49. Abarbanell AM, Coffey AC, Fehrenbacher JW et al (2009) Proinflammatory cytokine effects on mesenchymal stem cell therapy for the ischemic heart. Ann Thorac Surg 88:1036-1043
50. Aggarwal S, Pittenger MF (2005) Human mesenchymal stem cells modulate allogeneic immune cell responses. Blood 105: 1815-1822
51. Hare JM, Fishman JE, Gerstenblith G et al (2012) Comparison of allogeneic vs autologous bone marrow-derived mesenchymal stem cells delivered by transendocardial injection in patients with ischemic cardiomyopathy: the POSEIDON randomized trial. JAMA 308:2369-2379
52. Le Blanc K, Tammik C, Rosendahl K et al (2003) HLA expression and immunologic properties of differentiated and undifferentiated mesenchymal stem cells. Exp Hematol 31:890-896
53. Majumdar MK, Keane-Moore M, Buyaner D et al (2003) Characterization and functionality of cell surface molecules on human mesenchymal stem cells. J Biomed Sci 10:228-241
54. Tse WT, Pendleton JD, Beyer WM et al (2003) Suppression of allogeneic T-cell proliferation by human marrow stromal cells: implications in transplantation. Transplantation 75:389-397
55. Rasmusson I, Ringden O, Sundberg B et al (2003) Mesenchymal stem cells inhibit the formation of cytotoxic T lymphocytes, but not activated cytotoxic T lymphocytes or natural killer cells. Transplantation 76: 1208-1213
56. Spaggiari GM, Capobianco A, Becchetti S et al (2006) Mesenchymal stem cell-natural killer cell interactions: evidence that activated NK cells are capable of killing MSCs, whereas MSCs can inhibit IL-2-induced NK-cell proliferation. Blood 107:1484-1490
57. Ankrum JA, Ong JF, Karp JM (2014) Mesenchymal stem cells: immune evasive, not immune privileged. Nat Biotechnol 32: 252-260
58. Zangi L, Margalit R, Reich-Zeliger S et al (2009) Direct imaging of immune rejection and memory induction by allogeneic mesenchymal stromal cells. Stem Cells 27: 2865-2874
59. Fan M, Chen W, Liu W et al (2010) The effect of age on the efficacy of human mesenchymal stem cell transplantation after a myocardial infarction. Rejuvenation Res 13:429-438
60. O'Marcaigh AS, Cowan MJ (1997) Bone marrow transplantation for inherited diseases. Curr Opin Oncol 9:126-130
61. Huang XP, Sun Z, Miyagi Y et al (2010) Differentiation of allogeneic mesenchymal stem cells induces immunogenicity and limits their long-term benefits for myocardial repair. Circulation 122:2419-2429
62. Quevedo HC, Hatzistergos KE, Oskouei BN et al (2009) Allogeneic mesenchymal stem cells restore cardiac function in chronic ischemic cardiomyopathy via trilineage differentiating capacity. Proc Natl Acad Sci U S A 106:14022-14027
63. Makkar RR, Price MJ, Lill M et al (2005) Intramyocardial injection of allogenic bone marrow-derived mesenchymal stem cells without immunosuppression preserves cardiac function in a porcine model of myocardial infarction. J Cardiovasc Pharmacol Ther 10:225-233
64. Shi Y, Hu G, Su J et al (2010) Mesenchymal stem cells: a new strategy for immunosuppression and tissue repair. Cell Res 20:510-518
65. Soehnlein O, Lindbom L (2010) Phagocyte partnership during the onset and resolution of inflammation. Nat Rev Immunol 10: 427-439
66. Frangogiannis NG (2012) Regulation of the inflammatory response in cardiac repair. Circ Res 110:159-173
67. Jordan JE, Zhao ZQ, Vinten-Johansen J (1999) The role of neutrophils in myocardial ischemia-reperfusion injury. Cardiovasc Res 43:860-878
68. Ortiz LA, Dutreil M, Fattman C et al (2007) Interleukin 1 receptor antagonist mediates the antiinflammatory and antifibrotic effect of mesenchymal stem cells during lung injury. Proc Natl Acad Sci U S A 104:11002-11007
69. Volarevic V, Al-Qahtani A, Arsenijevic N et al (2010) Interleukin-1 receptor antagonist (IL-1Ra) and IL-1Ra producing mesenchymal stem cells as modulators of diabetogenesis. Autoimmunity 43:255-263
70. Nemeth K, Leelahavanichkul A, Yuen PS et al (2009) Bone marrow stromal cells attenuate sepsis via prostaglandin E(2)-dependent reprogramming of host macrophages to increase their interleukin-10 production. Nat Med 15:42-49
71. Chen L, Tredget EE, Wu PY et al (2008) Paracrine factors of mesenchymal stem cells recruit macrophages and endothelial lineage cells and enhance wound healing. PLoS One 3, e1886
72. Zhang QZ, Su WR, Shi SH et al (2010) Human gingiva-derived mesenchymal stem cells elicit polarization of m2 macrophages and enhance cutaneous wound healing. Stem Cells 28:1856-1868
73. Kim J, Hematti P (2009) Mesenchymal stem cell-educated macrophages: a novel type of alternatively activated macrophages. Exp Hematol 37:1445-1453
74. Gonzalez MA, Gonzalez-Rey E, Rico L et al (2009) Adipose-derived mesenchymal stem cells alleviate experimental colitis by inhibiting inflammatory and autoimmune responses. Gastroenterology 136:978-989
75. Porter KE, Turner NA (2009) Cardiac fibroblasts: at the heart of myocardial remodeling. Pharmacol Ther 123:255-278
76. van Amerongen MJ, Harmsen MC, van Rooijen N et al (2007) Macrophage depletion impairs wound healing and increases left ventricular remodeling after myocardial injury in mice. Am J Pathol 170:818-829
77. Cho DI, Kim MR, Jeong HY et al (2014) Mesenchymal stem cells reciprocally regulate the M1/M2 balance in mouse bone marrowderived macrophages. Exp Mol Med 46, e70
78. Jung YJ, Ju SY, Yoo ES et al (2007) MSC-DC interactions: MSC inhibit maturation and migration of BM-derived DC. Cytotherapy 9:451-458
79. Spaggiari GM, Abdelrazik H, Becchetti F et al (2009) MSCs inhibit monocyte-derived DC maturation and function by selectively interfering with the generation of immature DCs: central role of MSC-derived prostaglandin E2. Blood 113:6576-6583
80. Chiesa S, Morbelli S, Morando S et al (2011) Mesenchymal stem cells impair in vivo T-cell priming by dendritic cells. Proc Natl Acad Sci U S A 108:17384-17389
81. DelaRosa O, Lombardo E, Beraza A et al (2009) Requirement of IFN-gammamediated indoleamine 2,3-dioxygenase expression in the modulation of lymphocyte proliferation by human adipose-derived stem cells. Tissue Eng Part A 15:2795-2806
82. Najar M, Raicevic G, Boufker HI et al (2010) Mesenchymal stromal cells use PGE2 to modulate activation and proliferation of lymphocyte subsets: combined comparison of adipose tissue, Wharton’s Jelly and bone marrow sources. Cell Immunol 264:171-179
83. Ren G, Zhang L, Zhao X et al (2008) Mesenchymal stem cell-mediated immunosuppression occurs via concerted action of chemokines and nitric oxide. Cell Stem Cell 2:141-150
84. Chabannes D, Hill M, Merieau E et al (2007) A role for heme oxygenase-1 in the immunosuppressive effect of adult rat and human mesenchymal stem cells. Blood 110:3691-3694
85. Di Nicola M, Carlo-Stella C, Magni M et al (2002) Human bone marrow stromal cells suppress T-lymphocyte proliferation induced by cellular or nonspecific mitogenic stimuli. Blood 99:3838-3843
86. Uccelli A, Moretta L, Pistoia V (2008) Mesenchymal stem cells in health and disease. Nat Rev Immunol 8:726-736
87. Krampera M, Cosmi L, Angeli R et al (2006) Role for interferon-gamma in the immunomodulatory activity of human bone marrow mesenchymal stem cells. Stem Cells 24: 386-398
88. Corcione A, Benvenuto F, Ferretti E et al (2006) Human mesenchymal stem cells modulate B-cell functions. Blood 107:367-372
89. Merfeld-Clauss S, Gollahalli N, March KL et al (2010) Adipose tissue progenitor cells directly interact with endothelial cells to induce vascular network formation. Tissue Eng Part A 16:2953-2966
90. Traktuev DO, March KL, Tkachuk VA et al (2006) Adipose tissue stromal cells-multipotent cells with therapeutic potential for stimulation of angiogenesis in tissue ischemia. Kardiologiia 46:53-63
91. Makino S, Fukuda K, Miyoshi S et al (1999) Cardiomyocytes can be generated from marrow stromal cells in vitro. J Clin Invest 103:697-705
92. Li X, Yu X, Lin Q et al (2007) Bone marrow mesenchymal stem cells differentiate into functional cardiac phenotypes by cardiac microenvironment. J Mol Cell Cardiol 42:295-303
93. Augello A, De Bari C (2010) The regulation of differentiation in mesenchymal stem cells. Hum Gene Ther 21:1226-1238
94. Pijnappels DA, Schalij MJ, Ramkisoensing AA et al (2008) Forced alignment of mesenchymal stem cells undergoing cardiomyogenic differentiation affects functional integration with cardiomyocyte cultures. Circ Res 103:167-176
95. Genovese JA, Spadaccio C, Chachques E et al (2009) Cardiac pre-differentiation of human mesenchymal stem cells by electrostimulation. Front Biosci (Landmark Ed) 14:2996-3002
96. Wen L, Zhang C, Nong Y et al (2013) Mild electrical pulse current stimulation upregulates S100A4 and promotes cardiogenesis in MSC and cardiac myocytes coculture monolayer. Cell Biochem Biophys 65:43-55
97. Xu W, Zhang X, Qian H et al (2004) Mesenchymal stem cells from adult human bone marrow differentiate into a cardiomyocyte phenotype in vitro. Exp Biol Med (Maywood) 229:623-631
98. Hahn JY, Cho HJ, Kang HJ et al (2008) Pretreatment of mesenchymal stem cells with a combination of growth factors enhances gap junction formation, cytoprotective effect on cardiomyocytes, and therapeutic efficacy for myocardial infarction. J Am Coll Cardiol 51:33-943
99. Forte G, Minieri M, Cossa P et al (2006) Hepatocyte growth factor effects on mesenchymal stem cells: proliferation, migration, and differentiation. Stem Cells 24:23-33
100. Mohanty S, Bose S, Jain KG et al (2013) TGFbeta1 contributes to cardiomyogeniclike differentiation of human bone marrow mesenchymal stem cells. Int J Cardiol 163: 93-99
101. Li H, Yu B, Zhang Y et al (2006) Jagged1 protein enhances the differentiation of mesenchymal stem cells into cardiomyocytes. Biochem Biophys Res Commun 341: 320-325
102. Xu M, Wani M, Dai YS et al (2004) Differentiation of bone marrow stromal cells into the cardiac phenotype requires intercellular communication with myocytes. Circulation 110:2658-2665
103. Xie XJ, Wang JA, Cao J et al (2006) Differentiation of bone marrow mesenchymal stem cells induced by myocardial medium under hypoxic conditions. Acta Pharmacol Sin 27:1153-1158
104. Toma C, Pittenger MF, Cahill KS et al (2002) Human mesenchymal stem cells differentiate to a cardiomyocyte phenotype in the adult murine heart. Circulation 105:93-98
105. Rota M, Kajstura J, Hosoda T et al (2007) Bone marrow cells adopt the cardiomyogenic fate in vivo. Proc Natl Acad Sci U S A 104:17783-17788
106. Wagers AJ, Weissman IL (2004) Plasticity of adult stem cells. Cell 116:639-648
107. Wei F, Wang TZ, Zhang J et al (2012) Mesenchymal stem cells neither fully acquire the electrophysiological properties of mature cardiomyocytes nor promote ventricular arrhythmias in infarcted rats. Basic Res Cardiol 107:274
108. Rose RA, Jiang H, Wang X et al (2008) Bone marrow-derived mesenchymal stromal cells express cardiac-specific markers, retain the stromal phenotype, and do not become functional cardiomyocytes in vitro. Stem Cells 26:2884-2892
109. Silva GV, Litovsky S, Assad JA et al (2005) Mesenchymal stem cells differentiate into an endothelial phenotype, enhance vascular density, and improve heart function in a canine chronic ischemia model. Circulation 111:150-156
110. Hatzistergos KE, Quevedo H, Oskouei BN et al (2010) Bone marrow mesenchymal stem cells stimulate cardiac stem cell proliferation and differentiation. Circ Res 107(7):913-922
111. Wang T, Xu Z, Jiang W et al (2006) Cell-to-cell contact induces mesenchymal stem cell to differentiate into cardiomyocyte and smooth muscle cell. Int J Cardiol 109:74-81
112. Jazayeri M, Allameh A, Soleimani M et al (2008) Molecular and ultrastructural characterization of endothelial cells differentiated from human bone marrow mesenchymal stem cells. Cell Biol Int 32:1183-1192
113. Li Q, Xu X, Wang Z et al (2007) Investigation of canine mesenchymal stem cells differentiation to vascular endothelial cell in vitro. Sheng Wu Yi Xue Gong Cheng Xue Za Zhi 24:1348-1351
114. Oswald J, Boxberger S, Jorgensen B et al (2004) Mesenchymal stem cells can be differentiated into endothelial cells in vitro. Stem Cells 22:377-384
115. Martens TP, See F, Schuster MD et al (2006) Mesenchymal lineage precursor cells induce vascular network formation in ischemic myocardium. Nat Clin Pract Cardiovasc Med 3(Suppl 1):S18-S22
116. Kinnaird T, Stabile E, Burnett MS et al (2004) Local delivery of marrow-derived stromal cells augments collateral perfusion through paracrine mechanisms. Circulation 109: 1543-1549
117. Oskowitz A, McFerrin H, Gutschow M et al (2011) Serum-deprived human multipotent mesenchymal stromal cells (MSCs) are highly angiogenic. Stem Cell Res 6:215-225
118. Tang YL, Zhao Q, Zhang YC et al (2004) Autologous mesenchymal stem cell transplantation induce VEGF and neovascularization in ischemic myocardium. Regul Pept 117: 3-10
119. Rubina K, Kalinina N, Efimenko A et al (2009) Adipose stromal cells stimulate angiogenesis via promoting progenitor cell differentiation, secretion of angiogenic factors, and enhancing vessel maturation. Tissue Eng Part A 15:2039-2050
120. Tang J, Xie Q, Pan G et al (2006) Mesenchymal stem cells participate in angiogenesis and improve heart function in rat model of myocardial ischemia with reperfusion. Eur J Cardiothorac Surg 30:353-361
121. Markel TA, Wang Y, Herrmann JL et al (2008) VEGF is critical for stem cell-mediated cardioprotection and a crucial paracrine factor for defining the age threshold in adult and neonatal stem cell function. Am J Physiol Heart Circ Physiol 295:H2308-H2314
122. Yoon CH, Koyanagi M, Iekushi K et al (2010) Mechanism of improved cardiac function after bone marrow mononuclear cell therapy: role of cardiovascular lineage commitment. Circulation 121(18):2001-2011
123. Gomes SA, Rangel EB, Premer C et al (2013) S-nitrosoglutathione reductase (GSNOR) enhances vasculogenesis by mesenchymal stem cells. Proc Natl Acad Sci U S A 110:2834-2839
124. Traktuev DO, Merfeld-Clauss S, Li J et al (2008) A population of multipotent CD34-positive adipose stromal cells share pericyte and mesenchymal surface markers, reside in a periendothelial location, and stabilize endothelial networks. Circ Res 102:77-85
125. Ranganath SH, Levy O, Inamdar MS et al (2012) Harnessing the mesenchymal stem cell secretome for the treatment of cardiovascular disease. Cell Stem Cell 10:244-258
126. Strauer BE, Steinhoff G (2011) 10 years of intracoronary and intramyocardial bone marrow stem cell therapy of the heart: from the methodological origin to clinical practice. J Am Coll Cardiol 58:1095-1104
127. Song H, Song BW, Cha MJ et al (2010) Modification of mesenchymal stem cells for cardiac regeneration. Expert Opin Biol Ther 10:309-319
128. Frisch SM, Francis H (1994) Disruption of epithelial cell-matrix interactions induces apoptosis. J Cell Biol 124:619-626
129. Meredith JE, Fazeli B, Schwartz MA (1993) The extracellular matrix as a cell survival factor. Mol Biol Cell 4:953-961
130. Assis AC, Carvalho JL, Jacoby BA et al (2010) Time-dependent migration of systemically delivered bone marrow mesenchymal stem cells to the infarcted heart. Cell Transplant 19:219-230
131. Zhang XY, La Russa VF, Bao L et al (2002) Lentiviral vectors for sustained transgene expression in human bone marrow-derived stromal cells. Mol Ther 5:555-565
132. Gnecchi M, He H, Liang OD et al (2005) Paracrine action accounts for marked protection of ischemic heart by Akt-modified mesenchymal stem cells. Nat Med 11:367-368
133. Mangi AA, Noiseux N, Kong D et al (2003) Mesenchymal stem cells modified with Akt prevent remodeling and restore performance of infarcted hearts. Nat Med 9:1195-1201
134. Li W, Ma N, Ong LL et al (2007) Bcl-2 engineered MSCs inhibited apoptosis and improved heart function. Stem Cells 25:2118-2127
135. Song H, Kwon K, Lim S et al (2005) Transfection of mesenchymal stem cells with the FGF-2 gene improves their survival under hypoxic conditions. Mol Cells 19:402-407
136. Yang J, Zhou W, Zheng W et al (2007) Effects of myocardial transplantation of marrow mesenchymal stem cells transfected with vascular endothelial growth factor for the improvement of heart function and angiogenesis after myocardial infarction. Cardiology 107:17-29
137. Tang YL, Tang Y, Zhang YC et al (2005) Improved graft mesenchymal stem cell survival in ischemic heart with a hypoxia-regulated heme oxygenase-1 vector. J Am Coll Cardiol 46:1339-1350
138. Cheng Z, Ou L, Zhou X et al (2008) Targeted migration of mesenchymal stem cells modified with CXCR4 gene to infarcted myocardium improves cardiac performance. Mol Ther 16:571-579
139. Huang J, Zhang Z, Guo J et al (2010) Genetic modification of mesenchymal stem cells overexpressing CCR1 increases cell viability, migration, engraftment, and capillary density in the injured myocardium. Circ Res 106:1753-1762
140. Song H, Chang W, Lim S et al (2007) Tissue transglutaminase is essential for integrin-mediated survival of bone marrowderived mesenchymal stem cells. Stem Cells 25:1431-1438
141. Kanashiro-Takeuchi RM, Schulman IH, Hare JM (2011) Pharmacologic and genetic strategies to enhance cell therapy for cardiac regeneration. J Mol Cell Cardiol 51:619-625
142. Behfar A, Yamada S, Crespo-Diaz R et al (2010) Guided cardiopoiesis enhances therapeutic benefit of bone marrow human mesenchymal stem cells in chronic myocardial infarction. J Am Coll Cardiol 56:721-734
143. Ray R, Novotny NM, Crisostomo PR et al (2008) Sex steroids and stem cell function. Mol Med 14:493-501
144. Yang YJ, Qian HY, Huang J et al (2008) Atorvastatin treatment improves survival and effects of implanted mesenchymal stem cells in post-infarct swine hearts. Eur Heart J 29:1578-1590
145. Li N, Zhang Q, Qian H et al (2014) Atorvastatin induces autophagy of mesenchymal stem cells under hypoxia and serum deprivation conditions by activating the mitogen-activated protein kinase/extracellular signal-regulated kinase pathway. Chin Med J (Engl) 127:1046-1051
146. Haider H, Lee YJ, Jiang S et al (2010) Phosphodiesterase inhibition with tadalafil provides longer and sustained protection of stem cells. Am J Physiol Heart Circ Physiol 299:H1395-H1404
147. Chacko SM, Ahmed S, Selvendiran K et al (2010) Hypoxic preconditioning induces the expression of prosurvival and proangiogenic markers in mesenchymal stem cells. Am J Physiol Cell Physiol 299:C1562-C1570
148. Hu X, Yu SP, Fraser JL et al (2008) Transplantation of hypoxia-preconditioned mesenchymal stem cells improves infarcted heart function via enhanced survival of implanted cells and angiogenesis. J Thorac Cardiovasc Surg 135:799-808
149. Katritsis DG, Sotiropoulou P, Giazitzoglou E et al (2007) Electrophysiological effects of intracoronary transplantation of autologous mesenchymal and endothelial progenitor cells. Europace 9:167-171
150. Chen SL, Fang WW, Ye F et al (2004) Effect on left ventricular function of intracoronary transplantation of autologous bone marrow mesenchymal stem cell in patients with acute myocardial infarction. Am J Cardiol 94:92-95
151. Hare JM, Traverse JH, Henry TD et al (2009) A randomized, double-blind, placebo-controlled, dose-escalation study of intravenous adult human mesenchymal stem cells (prochymal) after acute myocardial infarction. J Am Coll Cardiol 54:2277-2286
152. Mohyeddin-Bonab M, Mohamad-Hassani MR, Alimoghaddam K et al (2007) Autologous in vitro expanded mesenchymal stem cell therapy for human old myocardial infarction. Arch Iran Med 10:467-473
153. Karantalis V, DiFede DL, Gerstenblith G et al (2014) Autologous mesenchymal stem cells produce concordant improvements in regional function, tissue perfusion, and fibrotic burden when administered to patients undergoing coronary artery bypass grafting: The Prospective Randomized Study of Mesenchymal Stem Cell Therapy in Patients Undergoing Cardiac Surgery (PROMETHEUS) trial. Circ Res 114:1302-1310
154. Heldman AW, DiFede DL, Fishman JE et al (2014) Transendocardial mesenchymal stem cells and mononuclear bone marrow cells for ischemic cardiomyopathy: the TAC-HFT randomized trial. JAMA 311:62-73
155. Trachtenberg B, Velazquez DL, Williams AR et al (2011) Rationale and design of the transendocardial injection of autologous human cells (bone marrow or mesenchymal) in chronic ischemic left ventricular dysfunction and heart failure secondary to myocardial infarction (TAC-HFT) trial: a randomized, double-blind, placebo-controlled study of safety and efficacy. Am Heart J 161:487-493
156. Williams AR, Trachtenberg B, Velazquez DL et al (2011) Intramyocardial stem cell injection in patients with ischemic cardiomyopathy: functional recovery and reverse remodeling. Circ Res 108:792-796
157. Anastasiadis K, Antonitsis P, Doumas A et al (2012) Stem cells transplantation combined with long-term mechanical circulatory support enhances myocardial viability in endstage ischemic cardiomyopathy. Int J Cardiol 155:e51-e53
158. Suncion VY, Ghersin E, Fishman JE et al (2014) Does transendocardial injection of mesenchymal stem cells improve myocardial function locally or globally? An analysis from the percutaneous stem cell injection delivery effects on neomyogenesis (POSEIDON) randomized trial. Circ Res 114:1292-1301
159. Lee JW, Lee SH, Youn YJ et al (2014) A randomized, open-label, multicenter trial for the safety and efficacy of adult mesenchymal stem cells after acute myocardial infarction. J Korean Med Sci 29:23-31
160. Abedin M, Tintut Y, Demer LL (2004) Mesenchymal stem cells and the artery wall. Circ Res 95:671-676
161. Hsu YC, Pasolli HA, Fuchs E (2011) Dynamics between stem cells, niche, and progeny in the hair follicle. Cell 144:92-105
162. Chimenti I, Gaetani R, Barile L et al (2012) Isolation and expansion of adult cardiac stem/progenitor cells in the form of cardiospheres from human cardiac biopsies and murine hearts. Methods Mol Biol 879: 327-338
163. Smith RR, Barile L, Cho HC et al (2007) Regenerative potential of cardiospherederived cells expanded from percutaneous endomyocardial biopsy specimens. Circulation 115:896-908
164. Karantalis V, Balkan W, Schulman IH et al (2012) Cell-based therapy for prevention and reversal of myocardial remodeling. Am J Physiol Heart Circ Physiol 303:H256-H270
165. Carr CA, Stuckey DJ, Tan JJ et al (2011) Cardiosphere-derived cells improve function in the infarcted rat heart for at least 16 weeks—an MRI study. PLoS One 6, e25669
166. Lee ST, White AJ, Matsushita S et al (2011) Intramyocardial injection of autologous cardiospheres or cardiosphere-derived cells preserves function and minimizes adverse ventricular remodeling in pigs with heart failure post-myocardial infarction. J Am Coll Cardiol 57:455-465
167. Li TS, Cheng K, Malliaras K et al (2012) Direct comparison of different stem cell types and subpopulations reveals superior paracrine potency and myocardial repair efficacy with cardiosphere-derived cells. J Am Coll Cardiol 59:942-953
168. Malliaras K, Li TS, Luthringer D et al (2012) Safety and efficacy of allogeneic cell therapy in infarcted rats transplanted with mismatched cardiosphere-derived cells. Circulation 125:100-112
169. Makkar RR, Smith RR, Cheng K et al (2012) Intracoronary cardiosphere-derived cells for heart regeneration after myocardial infarction (CADUCEUS): a prospective, randomised phase 1 trial. Lancet 379:895-904
170. Williams AR, Hatzistergos KE, Addicott B et al (2013) Enhanced effect of combining human cardiac stem cells and bone marrow mesenchymal stem cells to reduce infarct size and to restore cardiac function after myocardial infarction. Circulation 127:213-223
171. Mureli S, Gans CP, Bare DJ et al (2013) Mesenchymal stem cells improve cardiac conduction by upregulation of connexin 43 through paracrine signaling. Am J Physiol Heart Circ Physiol 304:H600-H609
172. Nowbar AN, Mielewczik M, Karavassilis M et al (2014) Discrepancies in autologous bone marrow stem cell trials and enhancement of ejection fraction (DAMASCENE): weighted regression and meta-analysis. BMJ 348:g2688
173. van Berlo JH, Kanisicak O, Maillet M et al (2014) c-kit cells minimally contribute cardiomyocytes to the heart. Nature 509(7500): 337-341